Vol. 23/No. 2 | OncologyLive

Making Progress Against the Blood-Brain Barrier

January 31, 2022

Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.

Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma

January 24, 2022

Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.